After confirming the status of hormone receptors and HER2 by a biopsy of metastatic breast cancer lesions, the determination of metastatic phenotype can be performed by repeated sampling, which can provide useful information on molecular changes and treatment customization [147]. Here, ERBB2 is linked to breast carcinoma.